Statins are unlikely to prevent blood clots, analysis finds

September 18, 2012

Despite previous studies suggesting the contrary, statins (cholesterol-lowering drugs) may not prevent blood clots (venous thrombo-embolism) in adults, according to a large analysis by international researchers published in this week's PLOS Medicine.

In 2009, an additional analysis of data from a called the JUPITER trial reported that the statin halved the risk of venous thromboembolic events among apparently healthy adults. However, this finding was based on a small number of patients who had thromboembolic events (34 vs 60). To gather more evidence about the possible benefits of statins, a group of international researchers led by Kazem Rahimi from the George Centre for Healthcare Innovation at the University of Oxford in the UK, combined the results (performed a meta-analysis) of 29 suitable published and unpublished of the effects of statins involving over 100 000 participants and more than 1000 events: Only two studies presented venous thrombotic events in the published report, but such events had been recorded as in all of the included trials, which the authors were able to include in their analysis.

In the combined analysis, the authors found that venous thrombosis occurred in 0.9% of people taking statins compared to 1% of people not taking statins, which suggests that statins have a very small, if any, effect. These results did not change when the authors excluded the findings of the JUPITER trial. The authors also found that there was no effect at all in people taking high doses and low doses of statins.

The authors conclude: "this study provides a more detailed assessment of the potential effects of statins (or higher dose statins) on venous thromboembolic events than has previously been possible. We were unable to confirm the large proportional reduction in risk suggested by some previous studies."

The authors add: "However, a more modest but perhaps clinically worthwhile reduction in venous thromboembolic events in some or all types of patient cannot be ruled out."

In an accompanying Perspective article, Frits Rosendaal from the Leiden University Medical Center in The Netherlands (uninvolved in the study) argues that even if the study cannot provide definite answers to the statin question, some tentative conclusions can be drawn. He says: "Firstly, that for the association between and venous thrombosis the methodologically strongest analysis shows at most a very small effect. Secondly, if we do not wish to discard the possibility of a beneficial effect for the whole class, any such effects are limited to rosuvastatin."

Explore further: Statins appear associated with reduced risk of recurrent cardiovascular events in men, women

More information: Rahimi K, Bhala N, Kamphuisen P, Emberson J, Biere-Rafi S, et al. (2012) Effect of Statins on Venous Thromboembolic Events: A Meta-analysis of Published and Unpublished Evidence from Randomised Controlled Trials. PLoS Med 9(9): e1001310. doi:10.1371/journal.pmed.1001310

Perspective article: Rosendaal FR (2012) Statins and Venous Thrombosis: A Story Too Good to Be True? PLoS Med 9(9): e1001311. doi:10.1371/journal.pmed.1001311

Related Stories

Statins appear associated with reduced risk of recurrent cardiovascular events in men, women

June 25, 2012
Cholesterol-lowering statin drugs appear to be associated with reduced risk of recurrent cardiovascular events in men and women, but do not appear to be associated with reduced all-cause mortality or stroke in women, according ...

Statins linked with lower depression risk in heart patients

February 24, 2012
Patients with heart disease who took cholesterol-lowering statins were significantly less likely to develop depression than those who did not, in a study by Mary Whooley, MD, a physician at the San Francisco VA Medical Center ...

Recommended for you

Five vascular diseases linked to one common genetic variant

July 27, 2017
Genome-wide association studies have implicated a common genetic variant in chromosome 6p24 in coronary artery disease, as well as four other vascular diseases: migraine headache, cervical artery dissection, fibromuscular ...

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

dogbert
1 / 5 (1) Sep 19, 2012
"Firstly, that for the association between statins and venous thrombosis the methodologically strongest analysis shows at most a very small effect. Secondly, if we do not wish to discard the possibility of a beneficial effect for the whole class, any such effects are limited to rosuvastatin."


Amazing. An article about statins which is not an endorsement.

Note that the JUPITER study is the only study of statins which actually showed a benefit to using statins and only because to participate in the JUPITER study, participants had to have high levels of c reactive protein. Any benefit was due to the anti-inflammatory effect of statins.

So to rephrase the above finding, we can discard the possibility of a beneficial effect for the whole class including rosuvastatin except for the anti-inflammatory effect.

Since there are much safer, cheaper and effective anti-inflammatory products (e.g.: aspirin), we can discontinue the use of statins altogether.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.